
IGC Pharma fell 42.4% from $0.33 to $0.19, behind the S&P 500's +10.2%. Its worst day was Oct 29 (−16.5%), and its low came Nov 16 at $0.18.
Nov 19, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
IGC Pharma shares rose 14.8%, while the S&P 500 rose 0.7%.
+14.8%, the year's best day · S&P 500 +0.7%
IGC Pharma shares fell 10.7%, while the S&P 500 rose 0.9%.
Story events cover the past 12 months · Times ET
−10.7% · S&P 500 +0.9%
EPS of $-0.01 beat the $-0.02 estimate on $213,000.00 revenue (est. $392,100.00).
−1.3% · S&P 500 −0.5%
IGC Pharma closed at its highest level of the year, 7.7% above where the year started.
+10.2% · S&P 500 +1.0%
EPS of $-0.02 was reported on $317,000.00 revenue.
0.0% · S&P 500 −0.1%
EPS of $-0.03 missed the $-0.02 estimate on $265,000.00 revenue (est. $160,000.00).
−6.0% · S&P 500 −0.5%
IGC Pharma shares fell 16.5%, while the S&P 500 fell 0.4%.
−16.5%, the year's worst day · S&P 500 −0.4%
EPS of $-0.02 beat the $-0.02 estimate on $328,000.00 revenue (est. $100,000.00).
+2.2% · S&P 500 +2.4%
Where it ended: a close of $0.19 on Nov 17, 2026. Up next: Q4 2027 earnings on Mar 11, 2027 (EPS est. $-0.02, revenue est. $280,000.00).
Nothing in the past 12 months.
All IGC dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for IGC and SPY from Benzinga historical bars. Not investment advice.